Bayer today announced new Phase III investigational data from the pivotal FINE-ONE trial showing that KERENDIA® (finerenone) significantly reduced urine albumin-to-creatinine ratio (UACR) from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback